Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				Pharmaceutical / Industry				CGX-635-CML-201 MDACC protocol #2005-0067, NCT00114959

Last Modified: 6/6/2008 First Published: 11/3/2006


2.		Phase II Study of Subcutaneous Homoharringtonine in Patients With Imatinib Mesylate-Resistant, Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia With the T315I BCR-ABL Gene Mutation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				CHEMGENEX-CGX-635-CML-202 NCT00375219, MDA-2006-0192, EUDRACT-2006-000176-32, OLMMC-06-033


3.		Open Label Study of Subcutaneous Homoharringtonine in Patients With Advanced CML

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CGX-635-CML-203 NCT00462943


4.		Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Active				18 and over				Pharmaceutical / Industry				CGX-635-205 NCT00675350

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute